NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 03 04:00PM ET
0.9001
Dollar change
-0.0999
Percentage change
-9.99
%
Index- P/E- EPS (ttm)-0.29 Insider Own4.05% Shs Outstand3.79M Perf Week7.15%
Market Cap3.41M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float3.63M Perf Month-3.59%
Enterprise Value1.53M PEG- EPS next Q- Inst Own4.71% Short Float0.08% Perf Quarter-6.24%
Income-0.99M P/S- EPS this Y- Inst Trans-51.00% Short Ratio0.06 Perf Half Y-23.40%
Sales0.00M P/B1.24 EPS next Y- ROA-20.80% Short Interest0.00M Perf YTD-20.32%
Book/sh0.72 P/C1.80 EPS next 5Y- ROE-37.96% 52W High2.98 -69.79% Perf Year-51.87%
Cash/sh0.50 P/FCF- EPS past 3/5Y1.50% -7.63% ROIC-36.23% 52W Low0.80 12.23% Perf 3Y-91.67%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility11.03% 6.50% Perf 5Y-
Dividend TTM- EV/Sales- EPS Y/Y TTM79.33% Oper. Margin- ATR (14)0.07 Perf 10Y-
Dividend Ex-Date- Quick Ratio2.78 Sales Y/Y TTM- Profit Margin- RSI (14)49.14 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio2.78 EPS Q/Q84.95% SMA201.45% Beta0.71 Target Price14.00
Payout- Debt/Eq0.01 Sales Q/Q- SMA50-5.88% Rel Volume79.74 Prev Close1.00
Employees- LT Debt/Eq0.00 EarningsMay 19 AMC SMA200-20.91% Avg Volume43.89K Price0.90
IPONov 28, 2018 Option/ShortNo / Yes EPS/Sales Surpr.- - Trades Volume3,499,741 Change-9.99%
Jun-26-25 07:00AM
May-19-25 07:00AM
Apr-30-25 07:00AM
Apr-28-25 07:00AM
Apr-17-25 07:45PM
07:00AM Loading…
Mar-19-25 07:00AM
Feb-24-25 07:00AM
Jan-29-25 07:00AM
Jan-17-25 05:00PM
Jan-06-25 07:00AM
Dec-19-24 07:00AM
Dec-12-24 09:17AM
Oct-24-24 07:00AM
Oct-18-24 04:00PM
Oct-17-24 08:00AM
05:00AM Loading…
Oct-09-24 05:00AM
Sep-13-24 07:00AM
Sep-12-24 05:30PM
Sep-06-24 05:30PM
Sep-03-24 12:30PM
Aug-29-24 07:00AM
Aug-23-24 07:00AM
Aug-20-24 07:00AM
Jun-04-24 08:30AM
May-20-24 11:53AM
May-17-24 07:00AM
Apr-30-24 01:54PM
Apr-22-24 07:00AM
Apr-08-24 07:30AM
07:00AM
05:00AM Loading…
Mar-27-24 05:00AM
Mar-19-24 09:30AM
05:00AM
Mar-11-24 07:00AM
Mar-04-24 07:00AM
Feb-15-24 07:00AM
Feb-01-24 08:46PM
Jan-15-24 07:00AM
Jan-03-24 07:00AM
Jan-02-24 07:00AM
Nov-30-23 07:30AM
Nov-29-23 07:00AM
Nov-10-23 07:00AM
Nov-08-23 05:00PM
Nov-02-23 07:00AM
Oct-27-23 05:30PM
Oct-25-23 05:00PM
07:00AM
Oct-23-23 09:10AM
Oct-20-23 08:42AM
Oct-12-23 07:00AM
Oct-04-23 07:00AM
Sep-28-23 07:00AM
Sep-11-23 07:00AM
Sep-07-23 07:00AM
Aug-29-23 07:00AM
Aug-04-23 05:00PM
Jun-29-23 08:00AM
Jun-23-23 08:51PM
Jun-06-23 07:00AM
May-24-23 07:00AM
May-04-23 07:00AM
Apr-21-23 07:00AM
Mar-14-23 07:00AM
Feb-07-23 07:00AM
Feb-01-23 07:00AM
Jan-19-23 07:00AM
Jan-03-23 07:00AM
Dec-19-22 07:00AM
Dec-08-22 07:00AM
Nov-28-22 07:00AM
Nov-25-22 05:45PM
Nov-16-22 07:00AM
Nov-08-22 03:40PM
Nov-03-22 05:00PM
10:15AM
Oct-26-22 07:00AM
Oct-25-22 07:00AM
Oct-07-22 06:02PM
Oct-04-22 08:30AM
Sep-19-22 07:00AM
Sep-01-22 07:00AM
Aug-22-22 07:00AM
Aug-04-22 07:00AM
Jul-22-22 08:00AM
Jul-19-22 07:00AM
Jul-13-22 07:00AM
Jul-07-22 07:00AM
Jun-21-22 07:00AM
Jun-13-22 08:55AM
Jun-08-22 07:00AM
Jun-06-22 07:00AM
May-25-22 08:00AM
May-05-22 07:00AM
May-03-22 07:00AM
Apr-20-22 07:00AM
Apr-12-22 07:00AM
Apr-07-22 07:00AM
Mar-31-22 07:00AM
Mar-23-22 07:00AM
XORTX Therapeutics, Inc. is a biopharmaceutical company. The firm engages in development and commercialization of innovative therapies. It focuses on drug therapies for rare orphan disease indications such as polycystic kidney disease, and the treatment of health consequences caused by chronic high serum uric acid or hyperuricemia, including Type 2 Diabetic Nephropathy, cardiovascular disease, and diabetes. The company was founded by Allen Davidoff on May 31, 2011 and is headquartered in Calgary, Canada.